165 related articles for article (PubMed ID: 27241581)
1. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
Pinto C; Bella MA; Capoluongo E; Carrera P; Clemente C; Colombo N; Cortesi L; De Rosa G; Fenizia F; Genuardi M; Gori S; Guarneri V; Marchetti A; Marchetti P; Normanno N; Pasini B; Pignata S; Radice P; Ricevuto E; Russo A; Tagliaferri P; Tassone P; Truini M; Varesco L
Future Oncol; 2016 Sep; 12(18):2071-5. PubMed ID: 27241581
[No Abstract] [Full Text] [Related]
2. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
[TBL] [Abstract][Full Text] [Related]
4. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
5. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George A; Kaye S; Banerjee S
Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
[TBL] [Abstract][Full Text] [Related]
6. Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
Rahman B; Lanceley A; Kristeleit RS; Ledermann JA; Lockley M; McCormack M; Mould T; Side L
J Med Genet; 2019 Mar; 56(3):195-198. PubMed ID: 29535157
[TBL] [Abstract][Full Text] [Related]
7. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
8. The integration of BRCA testing into oncology clinics.
Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S
Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Swisher E
Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
[TBL] [Abstract][Full Text] [Related]
10. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
11. [Management of hereditary ovarian cancer].
Joó JG; Ládi S; Nagy BZ; Langmár Z
Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
[TBL] [Abstract][Full Text] [Related]
12. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
[TBL] [Abstract][Full Text] [Related]
13. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
[TBL] [Abstract][Full Text] [Related]
14. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
[No Abstract] [Full Text] [Related]
16. Charity calls for routine BRCA testing of ovarian cancer patients.
Wise J
BMJ; 2013 Sep; 347():f5664. PubMed ID: 24046291
[No Abstract] [Full Text] [Related]
17. Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
Hoskins PJ
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):472-483. PubMed ID: 29735311
[TBL] [Abstract][Full Text] [Related]
18. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.
Afghahi A; Kurian AW
Curr Treat Options Oncol; 2017 May; 18(5):27. PubMed ID: 28439798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]